Business
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery.
About this update from Blue Water Ventures International, Inc.
[{"type":"text","content":"Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side EffectsFT. LAUDERDALE, FL / ACCESSWIRE / April 18, 2023 / Psycheceutical Bioscience, Inc (OTC PINK:BWVI) is a biotechnology company developing a new and unique mode of administration that has the potential to completely revolutionize the psychedelic mental health space. With a staggering 52.9 million adults living with mental illness in the U.S. alone and current treatments for mental health still using 1980s technology, millions of people have been left with no viable options to treat these debilitating diseases. While selective serotonin reuptake inhibitors (SSRIs) have been the mainstay for mental health treatment since the 1980s, they're not actually designed for long-term use and can have severe withdrawal symptoms. And in fact, new research has shown no evidence that low serotonin levels cause depression. Meanwhile, 1 in 6 American adults has reported taking a psychiatric drug, with the most widely prescribed form of antidepressant being an SSRI.Psychedelics To The RescueHowever, there is a growing interest and demand for the use of psychedelics for mental health treatment. The therapeutic benefits of psychedelics - especially the Schedule 3 compound ketamine - for treating mental health conditions like PTSD, anxiety, and depression have shown promising results in preclinical and clinical trials.To meet the desperate need for safe psychedelic medicines, Psycheceutical is developing a topical cream administration of ketamine which is designed to allow the drug to directly target the brain and bypass the GI tract and liver. This process is believed to eliminate the hallucinogenic effects of psychedelic drugs and significantly reduce the toxicity and adverse effects of these compounds.Currently, the ketamine treatment market is limited to intravenous (IV) or oral delivery. While effective, the cost of treatments like ketamine infusions can be between $400 and $2000 per infusion. Not only are these treatments expensive, but they also normally require a clinical setting for administration and monitoring. Side effects such as nausea, headaches, dizziness, disorientation and confusion are common with oral and IV ketamine routes of administration. Some patients also report experiencing un...